Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1 Infected Women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa

Benzer Materyaller

• Feasibility and Safety of ALVAC-HIV vCP1521 Vaccine in HIV- exposed Infants in Uganda: Results from the First HIV Vaccine Trial in Infants in Africa
  Yazar:: Kintu, Kenneth, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
  Yazar:: Punnee Pitisuttithum, ve diğerleri
  Baskı/Yayın Bilgisi: (2011-01-01)
• Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
  Yazar:: Pitisuttithum, Punnee, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
  Yazar:: de Souza, MS, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants
  Yazar:: Frey, Sharon E., ve diğerleri
  Baskı/Yayın Bilgisi: (2014)